Abstract:
Compounds of formula (I) have antibacterial activity, wherein Q represents -N(OH)CH(=O) or -C(=O)NH(OH); Y represents -C(=O)-, - C(=S)-, -S(=O)-, or -SO 2 -; R 1 represents hydrogen, C 1 -C 6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula -N(OH)CH(=O), a hydroxy, C l -C 6 alkoxy, C l -C 6 alkenyloxy, halogen, amino, C l -C 6 alkylamino, or di-( C 1 -C 6 alkyl)amino group; R 2 represents a substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 3 alkyl-O-C l -C 3 alkyl, C l -C 3 alkyl-S-C 1 -C 3 alkyl, cycloalkyl(C 1 -C 3 alkyl)-, aryl(C 1 -C 3 alkyl)-, heterocyclyl(C 1 -C 3 alkyl)-, or R 1 R 2 N-C 1 -C 3 alkyl group wherein R 1 represents hydrogen or C l -C 3 alkyl and R 2 represents C l -C 3 alkyl, or R 1 R 2 N- represents a cyclic amino group; R 3 and R 5 independently represent hydrogen or a substituted or unsubstituted C 1 -C 6 alkyl group or R 3 and R 5 taken together with the carbon and nitrogen atoms to which they are respectively attached form a saturated heterocyclic ring of from 5 to 7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionally be substituted; R 4 represents hydrogen or a substituted or unsubstituted C l -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, aryl, heterocyclyl, C l -C 3 alkyl-O-C I -C 3 alkyl, C 1 -C 3 alkyl-S-C 1 -C 3 alkyl, C 1 -C 3 alkyl-NH-(C I -C 3 alkyl)-, cycloalkyl(C 1 -C 3 alkyl)-, heterocyclic(C 1 -C 3 alkyl)- or aryl(C 1 -C 3 alkyl)- group; and A represents a primary, secondary or tertiary amino group or a group -R 6 , -OR 6 , wherein R 6 is a substituted or unsubstituted C l -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, aryl, heterocyclyl, C 1 -C 3 alkyl-O-(C 1 -C 3 alky)-l, C 1 -C 3 alkyl-S-(C 1 -C 3 alkyl)-, C l -C 3 alkyl-NH-(C 1 -C 3 alkyl)-, cycloalkyl(C 1 -C 3 alkyl)-, heterocyclic(C 1 -C 3 alky)-l or aryl(C 1 -C 3 alkyl)- group.
Abstract:
Compounds of formula (I) have antibacterial activity; wherein Q represents a radical of formula -N(OH)CH(=O) or formula -C(=O)NH(OH); Y represents -C(=O)-, -C(=S)-, -S(=O)-, or -SO 2 -; R 1 represents hydrogen, C l -C 6 alkyl or C l -C 6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula -N(OH)CH(=O), a hydroxy, C l -C 6 alkoxy, C 1 -C 6 alkenyloxy, halogen, amino, C l -C 6 alkylamino, or di-( C l -C 6 alkyl)amino group; R 2 represents a substituted or unsubstituted C l -C 6 alkyl, C l -C 3 alkyl-O-C 1 -C 3 alkyl, C 1 -C 3 alkyl-S-C l -C 3 alkyl, cycloalkyl(C l -C 3 alkyl)-, aryl(C 1 -C 3 alkyl)-, heterocyclyl(C l -C 3 alkyl)-, or R 1 R 2 N-C 1 -C 3 alkyl group wherein R 1 represents hydrogen or C 1 -C 3 alkyl and R 2 represents C l -C 3 alkyl, or R 1 R 2 N- represents a cyclic amino group; R 3 and R 4 taken together with the nitrogen atoms to which they are respectively attached form a saturated heterocyclic ring of from 4 to 7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionally be substituted; and A represents a primary, secondary or tertiary amino group or a group -R 5 , -OR 5 , wherein R 5 is a substituted or unsubstituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, aryl, heterocyclyl, C l -C 3 alkyl-O-C 1 -C 3 alkyl, C l -C 3 alkyl-S-C l -C 3 alkyl, cycloalkyl(C l -C 3 alkyl)-, heterocyclic(C l -C 3 alkyl, aryl(C l -C 3 alkyl)-or R 1 R 2 N-C 1 -C 3 alkyl group wherein R 1 represents hydrogen or C l -C 3 alkyl and R 2 represents C l -C 3 alkyl, or R 1 R 2 N- represents a cyclic amino group.
Abstract:
Compounds of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterised by abnormal cell growth and/or dysregulated apoptosis.
Abstract:
The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.